

Aisling Dolan – Operations Manager, TENI She/Her Sí/í



Nicola Cantwell
Pharmacist –
She/Her Sí/í
SETU, Caredoc, PATHI
Researching Rainbow
Ready Pharmacies



Sibéal Coll Pharmacist -They/she Siad/sí

THA, PATHI, Researcher, Advocate, Co-author BMC Cass Critique



TENI seeks to advance the rights and equality of all trans and gender diverse people in Ireland

We have three key areas of work:

- Support
- Training
- Policy

Sex vs Gender: What's the Difference?

Gender/Sex Assigned at birth: This is normally male or female and based on their anatomy or biology. Commonly referred to as 'sex assigned at birth', eg assigned female at birth (AFAB), assigned male at birth (AMAB)


Gender Identity: A person's deeply felt identification as male, female, another gender or no gender. The gender of which a person identifies, eg trans man, trans woman, cis man, cis woman, non-binary


Gender Expression: The external manifestation of a person's gender identity.

Sexuality: The people of whom a person may be physically, sexually and/or emotionally attracted to (e.g. gay, straight, bisexual, asexual, etc)



Binary, Non-Binary and Intersex





Binary Trans: A person whose gender identity is 'opposite' to the sex that they were assigned at birth. Identifying within the gender binary. For example: Trans Woman or Trans Man.

Non-Binary: An umbrella term to describe gender identities that are outside of the gender binary of 'Man' or 'Woman'. People who feel their gender identity is neither male nor female, both, none or a different gender identity altogether. For example: Non-Binary, Gender Fluid etc..

Intersex: An umbrella term to describe a person whose sex characteristics are not either all typically male or not all typically female at birth. This may include: External genitalia, internal reproductive anatomy, sex chromosomes, gonads - testicles or ovaries as well as certain sex hormone imbalances.

Transitioning

The process of "presenting" as your gender:

Social Transition: Coming out to family, friends, co-workers. Changing their name and/or pronouns. Changing outward appearance such as clothing, hair, accessories.

Legal Transition: Legally changing their name through deed-poll. Legally changing their gender through the Gender Recognition Act. Changing their name, title and/or gender marker on official documentation such as birth cert, passport, driving licence etc..

Medical Transition: Changing their physical appearance by accessing gender affirming healthcare such as: Hormone Replacement Therapy (HRT), Laser Hair Removal/Electrolysis, or other gender affirming surgeries.



Pronouns



"Hello, my name is Aisling. My pronouns are she/her. Can I ask what pronouns you use?"

Information available in Ireland



- Research conducted 2024 with Trans Healthcare Action
- No mention of us in the BNF, the IMF or the SPC!
- Our meds are there, but we are not...
- ...despite the meds we use being on the market for an average of 28 years







Medicines licensed in Ireland

Primary Sex Hormones

- Estradiol
- Testosterone

Blockers

- Spironolactone
- Cyproterone
- (Bicalutamide)
- Goserelin
- Buserelin
- Triptorelin
- Nafarelin



Other Sex Hormones

Progesterone

Long term contraception

- Levonorgestrel
- Etonogestrel
- Medroxyprogesterone

Hair loss

- Dutasteride
- Finasteride
- Minoxidil

Bread and butter = Primary Sex Hormone ± Hormone Blocker

*Ametop and EMLA: frequently requested anaesthetic creams for hair removal therapy



International gold standard guidelines

~260 pages





Appendix C GENDER-AFFIRMING HORMONAL TREATMENTS



Quick reference appendix

~1 A4 page!

answers most medicines questions

Appendix C GENDER-AFFIRMING HORMONAL TREATMENTS

- Table 1: Ideas about expected time frames for changes
- Table 2: Treatment risks
- Table 3: Regimens in youth
- Table 4: Regimens in adults (including doses)
- Table 5: Monitoring







Table 4. Hormone regimens in transgender and gender diverse adults*

Estrogen-based regimen (Transfeminine)

Estrogen

Oral or sublingual

Estradiol 2.0-6.0 mg/day

Transdermal

Estradiol transdermal patch 0.025-0.2 mg/day Estradiol gel various ‡ daily to skin

Parenteral

Estradiol valerate or cypionate 5-30 mg IM every 2 weeks

2-10 IM every week

Anti-Androgens

Spironolactone 100–300 mg/day Cyproterone acetate 10 mg/day**

GnRH agonist 3.75–7.50 mg SQ/IM monthly GnRH agonist depot formulation 11.25/22.5 mg SQ/IM 3/6

monthly

‡ Amount applied varies to formulation and strength

Testosterone-Based Regimen (Transmasculine) Transgender males

Testosterone

Parenteral

Testosterone enanthate/ 50–100 IM/SQ weekly or cypionate 100–200 IM every 2 weeks
Testosterone undecanoate 1000 mg IM every 12 weeks or 750 mg IM every 10 weeks

Transdermal testosterone

Testosterone gel 50-100 mg/day Testosterone transdermal patch 2.5–7.5 mg/day








^{*}Doses are titrated up or down until sex steroid hormone levels are in the therapeutic range. Hormone regimens do not reflect all formulations that are available in all pharmacies throughout the world. Hormone regimens may have to be adapted to what is available in local pharmacies.

^{**}Kuijpers et al (2021).

Rules of thumb

- ¼ of a 50mg cyproterone tablet is usually sufficient to suppress T while minimising SEs
 - Spironolactone doses are usually on the higher side
- Bicalutamide usually doesn't make sense to use in Ireland
 - Other high techs are GnRHa, which are far safer



- Not everyone wants or benefits, we need more research here
- T can may stop periods, but not a contraceptive!
 - No C/I to EHC for transmen + regular contraception can often be used FSRH+ASEC
- Dosage form selection is <u>primarily about patient preference</u>
 - Oral E can have slightly more SEs/Interactions due to FPM, consider avoid in polypharmacy, (esp avoid Premarin!)
- Don't overthink! The focus is usually more on getting sufficient hormone levels in blood
 - o some folks just need more!
- Listen to trans people patient educators advocacy groups
 - o Contraindications are rare, some cases may simply need extra planning/support



Essential blood tests for transgender people on hormone therapy

Evaluate every 3 months in the first year and then 1-2 times per year thereafter

Feminising Trans women Transfeminine (incl. non-binary) individuals		
Blood Tests	Target Ranges	
Oestradiol (E2)	Oestradiol (pmol/L*): 370-730	
Total testosterone (T)	Testosterone (nmol/L*): less than 1.7	
If taking cyproterone or bicalutamide: liver (LFT)		
If taking spironolactone: kidney (U&E) + potassium (morning sample)		
Preferred Time to Test		
Injection: just before next dose	Gel: few hours after application	
Patch: day after change		

Masculinising Transmen Transmasculine (incl. non-binary) individuals	
Blood Tests and Monitoring	Target Ranges
Total testosterone (T)	Testosterone (nmol/L*): 14-24
Haematocrit (FBC)	
Blood pressure + Lipids + HbA1c	
Preferred Time to Test	
Most injections: midway between doses	
Undecanoate injection (exception): just before next dose	
Gel: morning before applying or a few hours after application	

Regular blood testing is essential to providing person-centred care and engaging in a harm reduction approach for trans people.



Blood Test Quick Reference

Version 1 of PATHI's printable pocket guide for healthcare providers details the essential blood tests, monitoring, testing times, and target ranges for transgender people on hormone therapy based on the WPATH SOC8 guidelines. This is a key evidence-based resource to empower all healthcare providers to support their trans patients.

Download

Strengthening trans and gender diverse health, rights, and wellbeing.

The Professional Association for Trans Health Ireland (PATHI) is an all-island multidisciplinary organisation representing, supporting, and connecting those working to strengthen the health, rights, and wellbeing of all trans and gender diverse people across Ireland.

Become a member

Critically Appraising the Cass Report: Methodological Flaws and Unsupported Claims

Chris Noone^{a,*}, Alex Southgate^b, Alex Ashman^c, Élé Quinn^a, David Comer^a, Duncan Shrewsbury^d, Florence Ashley^e, Jo Hartland^f, Joanna Pashdag^g, John Gilmore^h, Natacha Kennedyⁱ, Thomas Woolley^j, Rachel Heath^k, Ryan Goulding^l, Victoria Simpson^m, Ed Kielyⁿ, Sibéal Coll^o, Margaret White^p, D.M. Grijseels^q, Maxence Ouafik^r, Quinnehtukqut McLamore^s

^a School of Psychology, University of Galway, University Road, H91 TK33, Galway, Ireland ^b School of Physics & Astronomy, Cardiff University, CF10 3AT, Cardiff, United Kingdom ^c Thames Valley School of Surgery, United Kingdom

^dDepartment of Medical Education, Brighton & Sussex Medical School, BN1 9PX, Brighton, United Kingdom

^e University of Alberta Faculty of Law, AB T6G 2R3, Edmonton, Canada
^fBristol Medical School, University of Bristol, 5 Tyndall Ave, BS8 1UD, Bristol, United Kingdom
^gDepartment of Psychology, Hawai' i Pacific University, 1 Aloha Tower Drive, HI 96813, Honolulu, United States

h School of Nursing, Midwifery and Health Systems, University College Dublin, 4 Stillorgan Rd, D04 C1P1, Belfield, Dublin, Ireland

ⁱDepartment of Educational Studies, Goldsmiths, 8 Lewisham Way, SE14 6NW, London, United Kingdom ^jSchool of Mathematics, Cardiff University, CF10 3AT, Cardiff, United Kingdom

k School of Psychological Sciences, University of Newcastle, Wallace Street, NE24DR, Newcastle upon Tyne, Australia

¹School of Nursing and Midwifery, University College Cork, College Rd, T12 K8AF, Cork, Ireland ^mDepartment of Psychology, Lancaster University, LA1 4YF, Bailrigg, Lancaster, United Kingdom ⁿSchool of Geography, Queen Mary University of London, Mile End Rd, E1 4NS, London, United Kingdom ^oTrans Healthcare Action, Ireland

PNHS Lothian, Waverley Gate, EH1 3EG, Edinburgh, Scotland

^qMax Planck Institute for Brain Research, Max-von-Laue-Straße 4, 60438, Frankfurt, Germany ^rGeneral Practice Department, University of Liège, Quartier Hopital B23, Avenue Hippocrate

13, 4000, Liège, Belgium

S Department of Psychological Sciences, University of Missouri at Columbia, McAlester Hall, 210, 320 S 6th St, MO 65201, Columbia, United States



Yale Law School

An Evidence-Based Critique of the Cass Review

An Evidence-Based Critique of "The Cass Review" on Gender-affirming Care for Adolescent Gender Dysphoria

Meredithe McNamara, MD MSc, Assistant Professor of Pediatrics, Yale School of Medicine

Kellan Baker, PhD, MPH, MA, Executive Director, Whitman-Walker Institute

Kara Connelly, MD, MCR, Associate Professor of Pediatrics, Division of Endocrinology, School of Medicine, Oregon Health & Science University

Aron Janssen, MD, Associate Professor of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine

Johanna Olson-Kennedy, MD, Professor of Clinical Pediatrics, Keck School of Medicine of University of Southern California

Ken C. Pang, FRACP, PhD. NHMRC Leadership Fellow and Senior Principal Research Fellow, Murdoch Children's Research Institute, VIC Australia

Ayden Scheim, PhD, Assistant Professor of Epidemiology, Dornsife School of Public Health, Drexel University

Jack Turban, MD, MHS, Assistant Professor of Psychiatry & Behavioral Sciences and Affiliate Faculty at the Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco

Anne Alstott, JD, Professor of Law, Yale Law School

Bad Actors: The Cass Report

- ~400 pages for the main report alone


 - focus: only youth; but misused against adults too
- Cochrane-recommended ROBIS tool
 - high risk of bias found across all 7 reviews
- Double standards
 - Incoherent scorings, recommendations
- Misrepresentation of our community
 - Restriction of care old myths resurface
- Bad science
 - Hiding limitations!!
- Our community needs your help
 - This is a hard time to be trans



- 67% use their local pharmacy for all prescriptions
- 15% use a different pharmacy for gender affirming prescriptions
- 32% have felt uncomfortable or discriminated against in a pharmacy
- 63% have felt anxious or stressed about going to pharmacy
- 30% have delayed going to pharmacy over concerns about how they are treated
- 33% felt they needed to educate the pharmacist in relation to their medication and why they were taking it




Ethical Dilemmas!



- Case by case basis
- Talk to patient
- Discuss with prescriber
- Discuss with colleagues
- Reference sources WPATH
- Evidence available
- Record details of discussions
- Make decision in best interests of patient

Ethical Dilemmas!







To be Rainbow Ready:

- Understanding and discretion
- Proper training for specific needs of gender diverse community
- Know rules of supply lots of EU scripts, High Techs on private Rx
- Understand guidelines for unlicensed medicine and off label use
- Clear privacy guidelines
- Support for 'DIYing' split boxes of needles, answer questions





Is your workplace inclusive of Gender-diverse Community?

- Knowledge of key LGBTQIA+ terms
- Inclusive communication
- Gender-related data management
- Visible symbols of support
- Trained staff
- Knowledge and patient-centred care
- 30% of survey participants said they thought pharmacists were doing their best despite constraints of healthcare system



Is your workplace inclusive of Gender-diverse Community?

- Knowledge of key LGBTom, is your
 Inclusive comportantly, is your
 Gende Most importantly, is your
 Gende Most importantly, is your
 Where that the
 Visible sworkplace somewhere that the
 Visible sworkplace somewhere community can
 Trained s gender-diverse community
 Trained s gender-diverse cared for and
 Knowledg feel safe, cared for and
 Knowledg feel safe, cared for and
 Jants said they thought pharmacists were doing their best despite

- pharmacists were doing their best despite constraints of healthcare system



Work in Progress

- Training for pharmacy technicians and pharmacy support staff from SETU/TENI
- Research into educational needs of pharmacists – gender diverse healthcare
- Building a community to design a Rainbow Ready Pharmacy Programme – click on QR code to sign up!
- Training programmes under construction by PATHI for Primary and Allied Healthcare Professionals

Rainbow Ready Pharmacies: Building a Community



Resources

- PATHI (collaborative forum, news and blood test quick reference guide) pathi.ie
- WPATH Standards of Care Version 8 wpath.org/publications/soc8/
- Noone et al. BMC Cass critique <u>bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-025-02581-7</u>
- McNamara et al. The Yale Critique law.yale.edu/sites/default/files/documents/integrityproject_cass-response.pdf
- TGEU 2022 trans health map Ireland ranked worst in Europe tgeu.org/trans-health-map-2022/
- BelongTo Being LGBT in Ireland <u>belongto.org/support-our-work/advocacy/lgbtq-research/being-lgbtqi-in-ireland-2024/</u>
- Rainbow Health Ontario some useful graphics for patient understandingrainbowhealthontario.ca/TransHealthGuide

Resources (continued)

- FSRH guidance on regular contraception and EHC in trans and nonbinary people –
 https://www.fsrh.org/Common/Uploaded%20files/documents/contraceptive-choices-and-sexual-health-for-transgender-non-binary-people-oct-2017.pdf
- "Drug—drug interactions between gender-affirming hormone therapy and antiretrovirals for treatment/prevention of HIV" – PreP and antiretrovirals are mostly well tolerated, detailed tables, WPATH says HIV prevention and treatment are not C/Is to care, also can use liverpool interactions checker - https://doi.org/10.1111/bcp.16097
- BMS guidelines on switching dosage forms and gels https://thebms.org.uk/wp-content/uploads/2024/02/15-BMS-TfC-HRT-preparations-and-equivalent-alternatives-JAN2024-B.pdf

Education Resources

- <u>eLearning Programme for Pharmacy and Health Professionals Supporting Medically</u> Underserved Communities
- Human Rights Foundation: Providing LGBTQ+-Inclusive Care and Services At Your Pharmacy
- Human Rights Foundation: Transgender and Gender Diverse Pharmacy Resource Guide
- National LGBTQIA+ Health Education Center (sic): Learning Resources
- Pride in Practice LGBT Foundation
- Transgender Europe: Guidelines to Human Rights-based Trans-specific Healthcare
- WPATH Global Education Initiative: Certified Training Courses